Cargando…

A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved....

Descripción completa

Detalles Bibliográficos
Autores principales: Shehata, Mahmoud M., Kandeil, Ahmed, Mostafa, Ahmed, Mahmoud, Sara H., Gomaa, Mokhtar R., El-Shesheny, Rabeh, Webby, Richard, Kayali, Ghazi, A. Ali, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963271/
https://www.ncbi.nlm.nih.gov/pubmed/31810359
http://dx.doi.org/10.3390/pathogens8040281
_version_ 1783488242696323072
author Shehata, Mahmoud M.
Kandeil, Ahmed
Mostafa, Ahmed
Mahmoud, Sara H.
Gomaa, Mokhtar R.
El-Shesheny, Rabeh
Webby, Richard
Kayali, Ghazi
A. Ali, Mohamed
author_facet Shehata, Mahmoud M.
Kandeil, Ahmed
Mostafa, Ahmed
Mahmoud, Sara H.
Gomaa, Mokhtar R.
El-Shesheny, Rabeh
Webby, Richard
Kayali, Ghazi
A. Ali, Mohamed
author_sort Shehata, Mahmoud M.
collection PubMed
description Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved. In this study, a chimeric DNA construct was designed to encode an influenza A/H1N1 NA protein which is flanking immunogenic amino acids (aa) 736–761 of MERS-CoV spike protein. Using the generated chimeric construct, a novel recombinant vaccine strain against pandemic influenza A virus (H1N1pdm09) and MERS-CoV was generated (chimeric bivalent 5 + 3). The chimeric bivalent 5 + 3 vaccine strain comprises a recombinant PR8-based vaccine, expressing the PB1, HA, and chimeric NA of pandemic 2009 H1N1. Interestingly, an increase in replication efficiency of the generated vaccine strain was observed when compared to the PR8-based 5 + 3 H1N1pdm09 vaccine strain that lacks the MERS-CoV spike peptide insert. In BALB/c mice, the inactivated chimeric bivalent vaccine induced potent and specific neutralizing antibodies against MERS-CoV and H1N1pdm09. This novel approach succeeded in developing a recombinant influenza virus with potential use as a bivalent vaccine against H1N1pdm09 and MERS-CoV. This approach provides a basis for the future development of chimeric influenza-based vaccines against MERS-CoV and other viruses.
format Online
Article
Text
id pubmed-6963271
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69632712020-02-26 A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice Shehata, Mahmoud M. Kandeil, Ahmed Mostafa, Ahmed Mahmoud, Sara H. Gomaa, Mokhtar R. El-Shesheny, Rabeh Webby, Richard Kayali, Ghazi A. Ali, Mohamed Pathogens Article Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved. In this study, a chimeric DNA construct was designed to encode an influenza A/H1N1 NA protein which is flanking immunogenic amino acids (aa) 736–761 of MERS-CoV spike protein. Using the generated chimeric construct, a novel recombinant vaccine strain against pandemic influenza A virus (H1N1pdm09) and MERS-CoV was generated (chimeric bivalent 5 + 3). The chimeric bivalent 5 + 3 vaccine strain comprises a recombinant PR8-based vaccine, expressing the PB1, HA, and chimeric NA of pandemic 2009 H1N1. Interestingly, an increase in replication efficiency of the generated vaccine strain was observed when compared to the PR8-based 5 + 3 H1N1pdm09 vaccine strain that lacks the MERS-CoV spike peptide insert. In BALB/c mice, the inactivated chimeric bivalent vaccine induced potent and specific neutralizing antibodies against MERS-CoV and H1N1pdm09. This novel approach succeeded in developing a recombinant influenza virus with potential use as a bivalent vaccine against H1N1pdm09 and MERS-CoV. This approach provides a basis for the future development of chimeric influenza-based vaccines against MERS-CoV and other viruses. MDPI 2019-12-02 /pmc/articles/PMC6963271/ /pubmed/31810359 http://dx.doi.org/10.3390/pathogens8040281 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shehata, Mahmoud M.
Kandeil, Ahmed
Mostafa, Ahmed
Mahmoud, Sara H.
Gomaa, Mokhtar R.
El-Shesheny, Rabeh
Webby, Richard
Kayali, Ghazi
A. Ali, Mohamed
A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
title A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
title_full A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
title_fullStr A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
title_full_unstemmed A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
title_short A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
title_sort recombinant influenza a/h1n1 carrying a short immunogenic peptide of mers-cov as bivalent vaccine in balb/c mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963271/
https://www.ncbi.nlm.nih.gov/pubmed/31810359
http://dx.doi.org/10.3390/pathogens8040281
work_keys_str_mv AT shehatamahmoudm arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT kandeilahmed arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT mostafaahmed arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT mahmoudsarah arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT gomaamokhtarr arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT elsheshenyrabeh arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT webbyrichard arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT kayalighazi arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT aalimohamed arecombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT shehatamahmoudm recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT kandeilahmed recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT mostafaahmed recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT mahmoudsarah recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT gomaamokhtarr recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT elsheshenyrabeh recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT webbyrichard recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT kayalighazi recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice
AT aalimohamed recombinantinfluenzaah1n1carryingashortimmunogenicpeptideofmerscovasbivalentvaccineinbalbcmice